Preview:

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF WISCONSIN
BAYER HEALTHCARE LLC;
Plaintiff,
v.                                                                                               Case No. 08-C-953
NORBROOK LABORATORIES, LTD.,
and NORBROOK, INC. USA;
Defendants.
DECISION AND ORDER
This Decision and Order addresses Plaintiff Bayer Healthcare LLC’s (“Bayer”)
motion to compel production pursuant to its April 11, 2011, discovery requests to Defendants
Norbrook  Laboratories,  Ltd.  and  Norbrook,  Inc.  U.S.A.’s                                    (collectively  referred  to  as
“Norbrook”), and Bayer’s contention regarding the July 8, 2011, declaration of Lillian Cromie,
Ph.D, (“Cromie”), Norbrook Laboratories, Ltd.’s Director of Licensing and its former Head
of Research and Development, that Norbrook filed in support of its opposition to the motion
to compel.    The discovery dispute relates to the scope of permissible discovery with respect
to Norbrook’s contention that claims 4 and 5 of United States Patent Number 5,756,506 (the
“‘506 patent”), which pertains to the treatment of animals with fluoroquinolones in a single




high dose to replace multiple lower doses are invalid, for lack of enablement as required by
35 U.S.C. § 112.  See ALZA Corp. v. Andrx Pharms., LLC, 603 F.3d 935, 940 (Fed. Cir. 2010).
ISSUE RELATING TO CROMIE DECLARATION
Subsequent to the completion of the briefing of Bayer’s motion to compel, with
the Court’s permission, Bayer filed a letter dated October 5, 2011, and attachments that it
stated supplemented and corrected its motion.   On October  12,  2011, Norbrook filed a
response to that letter, contesting Bayer’s contentions.    The Court addresses the issue raised
by the October 5, 2011, letter since it could impact resolution of the motion to compel.
Bayer asserts that Cromie’s subsequent deposition testimony reveals flaws in her
prior declaration.
REDACTED
Cromie indicated
that                                                                                               “to  my  knowledge,  only of  [sic]  a  few  of  the  fluoroquinolones  referenced  in  the
2




patent-in-suit in this case were commercially available around the 1995 timeframe when the
patent was filed. . .                                                                              . I do not specifically remember any fluoroquinolone injectable  products
available on the market for treatment of bovine respiratory disease in the 1995 timeframe.”
(Id. at ¶ 8.)  The foregoing statements in paragraph eight of Cromie’s declaration were based
on her knowledge and recollection.
At Cromie’s August 25, 2011, deposition, she was shown two documents that
Bayer obtained by means of an internet search which included a link to a CDC (“Center for
Disease Control”) article produced by that search.                                                 (Bayer’s October 5, 2011, letter,   Ex. B
290-92, referring to Exs. C & D to such letter.)   The CDC article indicates that by the 1995
time frame, three quinolones had been licensed:   marbofloxacin licensed in 1993 in cattle in
France; danofloxacin licensed in cattle and pigs in 1993 in Japan; orbifloxacin, licensed in
1993, in cattle and pigs; and “United Kingdom,” marbofloxacin, licensed in 1995 for cattle.
(Bayer’s October 5, 2011, letter, Ex. B 290-92, Ex. D.)  While Bayer contends that the search
results revealed flaws and inconsistencies in Cromie’s declaration, the  additional information
disclosed by those searches did not change what Cromie knew or recalled at the time of her
declaration.
Additionally, there is no indication  that                                                         “licensing” means  “commercially
available.”    The CDC article states “licensing for use does not necessarily mean that the drug
is  actually used, so even these data have to be considered with caution.”   (Bayer’s October 5,
2011, Letter, Ex. D  2 of  7.)    The CDC article also discusses the use of the drugs for
3




gastrointestinal diseases; not respiratory diseases.   The supplemental information provided
by Bayer will be considered by the Court, but it does not seriously undermine the proposition
advanced by Norbrook that the formulation work on non-fluroquinolone drugs on which Bayer
seeks discovery does not bear a logical relationship to the work on fluroquinolone drugs
because there is considerable difference between (a) the amount and nature of formulation and
testing work necessary to produce a drug with an active ingredient that is already commercially
available to treat a particular disease and (b) the  amount and nature of such work that would
be required to develop a drug with an active ingredient that has not been commercialized
and/or that is to be put to a new use.
BAYER’S MOTION TO COMPEL
Having addressed the preliminary issue regarding Cromie’s declaration, the
Court considers Bayer’s motion to compel Norbrook’s production of discovery sought by:
Requests Numbers 56 through 57, 62, and 65 through 66 of Bayer’s April 11, 2011, Request
for Production of Documents and Things (Numbers 47-73);  Interrogatories Numbers 24, and
26 through 29 of Bayer’s April 11, 2011, Set of Interrogatories (Numbers 23-35);   Rule
30                                                                                                 (b)(6) Deposition Topics Numbers  1 through  5 of Bayer’s April  11,  2011, Notice of
Deposition Topics (Numbers 1-25).   Bayer indicates that it has limited its   April 11, 2011,
discovery requests to the following injectable products:    Amoxicillin injectable referenced in
Norbrook’s   Suitability   Petition,   Number                                                      95P-0036/CP1;   Carprieve                                                               50   mg/ml;
Dihydrostreptomycin Sulfate  (NADA  065-013); Enovex  1.0% w/v; Norocarp  50 mg/ml;
4




Norocillin (NADA 065-010); Penicillin G Procaine Aqueous / Sterile Penicillin G Benzathine
(NADA  065-500); and its oxytetracycline formulations, including any information about
formulations referenced in Norbrook’s Suitability Petition, Number 92P-0490/CP1.    Bayer
also states  “where applicable its requests are further limited to information sufficient to show
the requested information.”  (Bayer Mot. Compel 2.)  Norbrook has only responded to Bayer’s
discovery requests as to fluoroquinolones.
Bayer’s motion to compel arises as a result of the disparity between Norbrook’s
response to the April 11, 2011, discovery requests and those drugs for which Bayer has
requested discovery.  Bayer contends that the principles of the formulation of fluoroquinolones
extend to formulations of other types of drugs and, therefore, it should be allowed to obtain
discovery  regarding  non-fluoroquinolones.    Norbrook  asserts  that  discovery  regarding
non-fluoroquinolones is not relevant and, even if it were relevant, any relevance would be far
outweighed  by  the  burden  associated  with  Norbrook’s  production  of  such  documents,
information, and testimony.
The present discovery issues are based on Norbrook’s   contention that claims
4 and 5 of the ‘506 patent, the only claims at issue in this action, are invalid because a person
of ordinary skill could not have prepared                                                           REDACTED
                                                                                                               u s i n g   t h e
disclosures of the ‘506 patent.   The “[f]ield of the [i]nvention” is described as “The . . .
treatment of animals with fluoro[]quinolones.   More specifically, the present invention relates
5




to “the use of fluoroquinolones in a single high dose to replace multiple lower doses.”   (‘506
patent, 1:10-12.)
Claims 4 and 5 read as follows (with claim 1 language incorporated in brackets):
4.                                                                                                [A process for treating a bacterial infection], wherein the
bacterial infection is bovine respiratory disease, [in an animal in
need  thereof  comprising  administering  to  said  animal  a
pharmaceutically   effective   composition   comprising   a
fluoroquinolone, an ester, or a salt thereof in one high dose, single
treatment.]
5. The process of claim 4 wherein the bovine respiratory disease
is caused by Pasteurella, haemolytica or Pasteurella multocida.
(Id. at 4:10-14 & 24-29 (emphasis added).)  Simply put the dispute between the parties is the
breadth of the discovery that is relevant to Norbrook’s enablement contentions.
Relevant Law
Rule 26(b) of the Federal Rules of Civil Procedure provides that “[p]arties may
obtain discovery regarding any nonprivileged matter that is relevant to any party’s claim or
defense - including the existence, description, nature, custody, condition, and location of any
documents or other tangible things and the identity and location of persons who know of any
discoverable matter.”   It also explains that “[r]elevant information need not be admissible at
the trial if the discovery appears reasonably calculated to lead to the discovery of admissible
evidence.”   Fed. R. Civ. P. 26(b) (emphasis added.)   Nonetheless, “[a]ll discovery is subject
to the limitations imposed by Rule 26(b)(2)(C).”   Id.
6




The limitations imposed by Rule 26(b)(2)(C) include the requirement that the
Court “must” limit the frequency or extent of discovery if it determines that “the discovery
sought is unreasonably cumulative or duplicative, or can be obtained from some other source
that  is  more  convenient,  less  burdensome,  or  less  expensive.”  See  Fed.  R.  Civ.  P.
26                                                                                                 (b)(2)(C)(i).  The Court must also impose such limitations if it determines that “the burden
or expense of the proposed discovery outweighs its likely benefit, considering the needs of the
case, the amount in controversy, the parties’ resources, the importance of the issues at stake
in the action, and the importance of the discovery in resolving the issues.”   See Fed. R. Civ.
P. 26(b)(2)(C)(iii).
District courts have broad discretion in determining motions to compel.   See
Peals v. Terre Haute Police Dep’t, 535 F.3d 621, 629 (7th Cir. 2008).   In responding to a
motion to compel discovery, the party that objects to the discovery request has the burden of
demonstrating, with specificity, why the information sought is not discoverable.  Graham v.
Casey’s Gen. Stores, 206 F.R.D. 251, 254 (S.D. Ind. 2002).
Since the discovery dispute relates to Norbrook’s enablement contentions, a
brief summary of the relevant legal principles is helpful.                                         “To be enabling, the specification
must teach those skilled in the art to make and use the full scope of the claimed invention
without undue experimentation.”  Genentech, Inc. v. Novo Nordisk, 108 F.3d 1361, 1365 (Fed.
Cir. 1997) (emphasis added).   If the specification requires one of ordinary skill in the art to
perform “undue experimentation” to practice the invention as broadly as it is claimed, the
7




patent is invalid for lack of enablement.   In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988)
(emphasis added).   However,  “[e]nablement is not precluded by the necessity for some
experimentation . . . ,” and “[a] patent need not disclose what is well known in the art.”  Id. at
737,                                                                                                               735.                                                         Factors  to  consider  in  determining  whether  a  disclosure  requires  undue
experimentation include “(1) the quantity of experimentation necessary, (2) the amount of
direction or guidance presented, (3) the presence or absence of working examples, (4) the
nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7)
the predictability or unpredictability of the art, and (8) the breadth of the claims.”   Id.
Analysis
In asserting that discovery should include drugs other than fluoroquinolones,
Bayer relies on parts of the report of Norbrook’s   expert, Stephen R. Bryn, Ph.D. (“Bryn”).1
Bayer relies upon Bryn’s statement at page 18 of his 21 page report that “[t]he trial and error
process required to determine a ‘pharmaceutically effective composition’ demonstrated by
Bayer  is  typical  of  pharmaceutical  companies.    Treating  diseases  in  animals  requires
considerable  effort  by  pharmaceutical  companies  to  ensure  that  a  non-toxic,  effective
formulation is developed.”                                                                                         (Bayer's Mem. Support Mot. Compel 5 (quoting Simpson Decl.
filed June 17, 2011, Ex. A (Bryn Report), ¶ 53).)  Bayer further notes that, in his report  Bryn
relies on examples and principles from other drug classes than fluoroquinolones.   (Id. (citing
1
Bryn was the Head of the Department of Industrial and Physical Pharmacy at Purdue University from 1994
to 2009, and is currently the Charles B . Jordan Professor of Medicinal Chemistry at Purdue, a position he   was
appointed to in 1992.
8




Simpson Decl. filed June 17, 2011, Ex. A 10-11, 19).)   From this, Bayer infers that it is
entitled to discovery regarding Norbrook’s other formulation research which Bayer believes
will discredit Norbrook’s contentions regarding the difficulty of preparing fluoroquinolone
formulations.
Bayer also relies on the three page declaration of one of its experts, Anthony
2
Palmieri III, Ph.D. (“Palmieri”).                                                                            ( Id. at 5-6 (citing Simpson Decl. filed June 17, 2011, Ex. E
2-3).)    Palmieri states that while Byrn “directs his comments in some (but not all) portions of
his report to fluoroquinolones, the scientific issues that he addresses apply more generally to
the formulation of drug products in other classes as well.   Experience and information
regarding the formulation of drugs in other classes other than fluoroquinolones would certainly
be relevant to an effort to refute the statements by . . . Bryn and his conclusions.”                        (Simpson
Decl. filed June 17, 2011, Ex. E ¶ 7.)
Bryn’s report contains highly detailed explanations regarding why the patent
specification does not provide sufficient information for enablement.
REDACTED
2
Palmieri is presently on the faculty at the University of Florida College of Pharmacy in the Department of
Pharmaceutics.
9




REDACTED
10




REDACTED
The Court concludes that, in asserting that Bryn’s report provides a basis for the
relevance of Norbrook’s work on non-fluoroquinolones, Bayer has selectively read his report.
Moreover, when read in full, Bryn’s report establishes that the relevant chemical class of
compounds with respect to  enablement are fluoroquinolones.    Discovery regarding the
formulations of other chemical groups that are used as injectable drugs is not likely to lead to
the discovery of admissible evidence on the enablement issue in this action.  (See also, Cromie
Decl. ¶¶ 6-10.)   Norbrook has met its burden of establishing that discovery regarding the
formulation of drugs in other classes other than fluoroquinolones is not likely to lead to the
discovery of admissible evidence regarding enablement.  3Palmieri’s statements to the contrary
are conclusory and without factual support in his declaration.
The three cases that Bayer relies upon in its reply brief to argue that the
discovery sought is highly relevant to this case are not helpful. (See Bayer Reply Mem.
Support Mot. Compel 9-10 (citing cases).)  Compagnie Noga d’Importation et d’Exportation
S.A.   v. Russian Fed’n, No. 00 Civ. 0632 (WHP), 2008 WL 3833257, at *6 (S.D.N.Y. Aug.
3
Notably, several district courts have determined that discovery must be limited by what is claimed in the
patent.  See Wyeth v. Abbott Labs., No. 08-230 (JAP), 2011 WL 2429318, at *7 (D .N .J. June 13, 2011) (limiting scope
of third-party subpoena to the specific use claimed in the patent at issue); Pfizer Inc. v. Teva Pharms. USA , Inc., No.
08-1331                                                                                                                    (DMC),  2009  WL  1587893,  *2  (D.N .J.  June  4,  2009)  (where  the  patent-in-suit  claimed  only  oral
formulations, the inventors’ efforts to develop nonoral formulations were irrelevant and any claim of relevance was
purely speculative); Monsanto Co. v. Aventis Cropscience, N.V., No. 4:00CV 1915 ERW , slip op. at 11-13 (E.D . Mo.
July 18, 2002)  (Dkt. No. 150)  (where the patent-in-suit involved “truncated” crop gene resistant to insects, the
plaintiff's discovery demands for the defendants’ work on “untruncated” crop gene were overbroad).
11




15, 2008), cited for the statement that the “[Plaintiff’s] own documents undermine its expert’s
interpretation and support Defendant’s expert’s interpretation,” involved the weighing of
expert reports and does not relate to the scope of permissible discovery.    Cooley v. Lincoln
Elec. Co., 776 F. Supp. 2d 511,   2011 WL 841535, at *17 (N.D. Ohio Mar. 7, 2011), involves
a discussion of the weighing of expert testimony regarding whether there is a reasonable
disagreement  among  experts  that  manganese  in  welding  fumes  can  cause  manganese
poisoning.   Cooley does not discuss the scope of   discovery or relevance.
Bitler Inv. Venture II, LLC v. Marathon Ashland Petrol. LLC, No. 1:04-CV-477,
2007 WL 465444, at *7 (N.D. Ind. Feb. 7, 2007), addresses  the scope of discovery regarding
a damage expert’s opinions and concluded after an in camera inspection that emails from a
plaintiff to the expert were relevant to expert’s opinion because they revealed that plaintiff’s
potential influence on the expert, thereby impacting the credibility of that expert’s report.
Bitler does not support Bayer’s contention of relevance.
In addition, even if this Court had concluded that the information is relevant,
Norbrook has demonstrated that the burden or expense of the proposed discovery outweighs
its likely benefit, considering the needs of the case, the amount in controversy, the parties’
resources, the importance of the issues at stake in the action, and the importance of the
discovery in resolving the issues.
REDACTED
12




REDACTED
Norbrook has demonstrated with specificity the excessive burden that the
discovery will place upon Norbrook.   Bayer indicates Norbrook overstates what Bayer is
requesting,  and that while Bayer wants documents relating to formulation development work,
it has “consistently indicated its willingness to accept summary documents,” (Bayer Reply
Mem. Support Mot. Compel 13.)  However, there is no indication that Norbrook has summary
documents regarding its formulation development work.   Thus, Bayer has failed to rebut
Norbrook’s showing that the requested discovery would create an undue burden.    Because
the burden that the discovery would impose upon Norbrook outweighs its relevance, Bayer’s
motion to compel production pursuant to its April 11, 2011, discovery requests to Norbrook
is also denied on this basis.
Because many of the documents relating to and discussed in this Decision and
Order  relate to confidential information and are sealed, this Court finds good cause to seal this
13




Decision and Order.  See Cnty. Materials Corp. v. Allan Block Corp., 502 F.3d 730, 740 (7th
Cir. 2007).  The sealing order will expressly provide that any party and any interested member
of the public may challenge the sealing of those papers.   See id.    A redacted version of this
Decision and Order will be filed in the public record.
NOW , THEREFORE, BASED ON THE FOREGOING, IT IS HEREBY
ORDERED THAT:
Bayer’s   motion to compel production pursuant to Bayer’s April 11, 2011,
discovery requests (Docket No. 201) is DENIED.
The Clerk of Court is DIRECTED TO SEAL this Decision and Order.
Any party and any interested member of the public MAY CHALLENGE the
sealing of this Decision and Order.
The Clerk of Court is also DIRECTED TO FILE A REDACTED VERSION
of this Decision and Order.
Dated at Milwaukee, Wisconsin, this 6th day of December, 2011.
BY THE COURT:
HON. RUDOLPH T. RANDA
U.S. District Judge
14

Download 28153.pdf

Wisconsin Law